Skip to main content

Barbara Dudley Alexander

Professor of Medicine
Medicine, Infectious Diseases
Duke Box 102359, Durham, NC 27710
315 Trent Drive, Hanes House, Room 163A, Durham, NC 27710

Overview


Clinical research related to infectious complications of solid organ and bone marrow transplantation, with a particular interest in the treatment and rapid diagnosis of fungal disease. Training the next generation of Transplant Infectious Disease Physicians is a special focus of mine as the Principal Investigator of our Interdisciplinary T32 Training Program funded the NIH.

Current Appointments & Affiliations


Professor of Medicine · 2014 - Present Medicine, Infectious Diseases, Medicine
Professor of Pathology · 2014 - Present Pathology, Clinical Science Departments

Recent Publications


Plasma Microbial Cell-free DNA Metagenomic Sequencing for Diagnosis of Invasive Fungal Diseases Among High-risk Outpatient and Inpatient Immunocompromised Hosts.

Journal Article Clin Infect Dis · December 24, 2025 BACKGROUND: New and minimally invasive tools to aid the diagnosis of invasive fungal diseases (IFD) are urgently needed as the immunocompromised population at highest risk increases. Advancements in molecular technology have rendered new diagnostics more r ... Full text Link to item Cite

Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis.

Journal Article J Antimicrob Chemother · December 19, 2025 BACKGROUND: All triazoles decrease the metabolism of calcineurin inhibitors (CNIs) and mammalian target of rapamycin (mTOR) inhibitors through CYP3A4 and P-glycoprotein inhibition leading to increased exposure and the potential for serious adverse events ( ... Full text Link to item Cite

Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study.

Journal Article Lancet Infect Dis · November 2025 BACKGROUND: Only a small number of antifungal therapies for invasive fungal disease (IFD) are currently available, and many pathogens are resistant to one or more of these therapies. Olorofim, the first orotomide antifungal agent to be developed, is active ... Full text Link to item Cite
View All Publications

Recent Grants


Novel Host-Response Biomarker Diagnostics for Invasive Aspergillosis

ResearchCo-Mentor · Awarded by National Institute of Allergy and Infectious Diseases · 2024 - 2029

Tri-Institutional Molecular Mycology and Pathogenesis Training Program

Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029

UAB - Clinical and Applied Research Strategies for the Prevention and Control of Fungal Diseases

ResearchPrincipal Investigator · Awarded by University of Alabama at Birmingham · 2023 - 2028

View All Grants

Education, Training & Certifications


East Carolina University · 1993 M.D.